Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid
peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Tumor evolution is driven by the progressive acquisition of genetic and epigenetic
alterations that enable uncontrolled growth and expansion to neighboring and distal tissues …

Single-cell RNA sequencing (scRNA-seq) distinguishes cell types, states and lineages
within the context of heterogeneous tissues. However, current single-cell data cannot …

PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

A thorough interrogation of the immune landscape is crucial for immunotherapy strategy
selection and prediction of clinical responses in non-small-cell lung cancer (NSCLC) …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …